この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。
ビジネス · 2025/7/21 分で読めます
Determination of Regulatory Review Period for Purposes of Patent Extension; ELREXFIO; Correction
ローカル自動翻訳 · 情報源の原言語
概要
The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register on May 12, 2025. The document, entitled "Determination of Regulatory Review Period for Purposes of Patent Extension; ELREXFIO," announced the determination of the regulatory review period for ELREXFIO (elranatamab-bcmm) for purposes of patent extension. The document was published with only one of two docket numbers. This document corrects that error.
情報源の原言語: Federal Register — Food and Drug Administration原文の発表を開く →